MabVax Therapeutics Closes Two Licensing Agreements with Sloan-Kettering Institute for Cancer Research
News Aug 14, 2008
MabVax Therapeutics Inc. has announced the completion of two separate licensing agreements with the Memorial Sloan-Kettering Cancer Center’s Sloan-Kettering Institute for Cancer Research (SKI).
The first license agreement grants MabVax exclusive development and commercialization rights to multiple vaccines against recurrent cancer for six different types of cancer. MSKCC plans to initiate Phase I clinical trials in each of these types of cancer this year or early next year.
Upon successful demonstration of immunogenicity and tolerability in the Phase I trials in sarcoma and small cell lung cancer, MabVax will initiate Phase II trials in these two cancer types.
In addition to MabVax’s efforts, MSKCC is planning to conduct Phase II trials with the licensed vaccines in ovarian and breast cancer. Pending successful outcomes, MabVax can assume responsibility for continued development and eventual commercialization of these vaccines.
The second license agreement grants MabVax exclusive rights to the use of the licensed vaccines and lymphocytes from successfully vaccinated clinical trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline of fully human monoclonal antibody products against each of the vaccine targets expressed on the surface of the cancer cells.
By rescuing antibodies from a selection of patients who generate a useful immune response, MabVax can select the optimal antibodies and develop them as either stand alone products or as combination products with the vaccines. MabVax has established a laboratory and office in the San Diego area to launch this effort.
"The completion of these two agreements establishes the scientific foundation of the company and firmly set us on a research, and development pathway that we hope will address a significant unmet medical need by preventing recurrence in certain types of cancers and prolonging patient survival,” said David Hansen the company’s President and Chief Executive Officer.
Philip Livingston, M.D., the company’s Chief Science Officer and co-founder of MabVax added “Targeting residual circulating cancer cells and micrometastasis with passively administered or vaccine induced antibodies against multiple targets is an approach well suited to eradicating the cancer cells that cause metastatic disease. Our clinical trials over the next several years will tell us a great deal about the utility of this approach to treating cancer."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019